EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study

Xin Chang Zou, Lie Yu Xu, Yu Yang Yuan, Gu Yue Zhang, Jian Biao Huang, Tao Zeng

Frontiers in Immunology · 29.04.2026 · 17

DOI: 10.3389/fimmu.2026.1815591 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Frontiers in Immunology, online erschienen am 29.04.2026. Verfasst von Xin Chang Zou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Second Affiliated Hospital of Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Urologic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives The combination of disitamab vedotin (RC48) with PD-1 inhibitors has shown synergistic potential in preclinical studies for treating advanced urothelial carcinoma (UC). Nevertheless, real-world evidence regarding its clinical efficacy and safety profile remains limited. This multicenter real-world study aims to comprehensively evaluate the therapeutic outcomes and safety of RC48 combined with PD-1 inhibitors in patients with locally advanced or metastatic urothelial carcinoma (La/mUC), with a particular focus on analyzing the impact of comorbidities on treatment efficacy and prognosis. Patients and methods A retrospective analysis was conducted on 132 patients with La/mUC who received RC48 combined with a PD-1 inhibitor at six treatment centers between June 2022 and March 2024. Clinical–pathological characteristics, treatment regimens, and follow-up data were collected from electronic medical record systems. Efficacy outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR). Safety was assessed by recording treatment-related adverse events (TRAEs), with efficacy evaluated across different disease subpopulations. Survival curves were generated using the Kaplan–Meier method, and Cox proportional hazards regression was employed for survival analysis.

Results

A total of 132 patients with La/mUC were enrolled. The RC48 plus PD-1 inhibitor regimen demonstrated an ORR of 71.21% (95% CI: 62.97%–78.25%) and a DCR of 88.64% (95% CI: 82.10%–92.99%). The median PFS was 21 months (95% CI: 14–24 months), and the median OS was not reached. Kaplan–Meier analyses indicated that comorbid conditions such as hypertension, diabetes, hyperlipidemia, or renal insufficiency did not compromise efficacy, with similar PFS and OS observed across subgroups. The most common TRAEs were fatigue (38.64%), nausea (35.61%), anemia (32.58%), pruritus (28.79%), and peripheral neuropathy (23.48%). The incidence of grade 3 adverse events was 13.64%, with no grade 4 or higher events reported.

Conclusions

The RC48 plus PD-1 inhibitor treatment regimen demonstrated clear antitumor activity and manageable safety in a multicenter real-world study of patients with La/mUC, with consistent therapeutic effects observed in patients with comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellUrologic NeoplasmsUrinary Bladder NeoplasmsHumansFemaleMaleRetrospective StudiesAgedPrognosisMiddle AgedTreatment OutcomeProgrammed Cell Death 1 ReceptorNeoplasm MetastasisAged, 80 and overAntibodies, MonoclonalOligopeptides

Stichwörter der Autor:innen

PD-1 inhibitordisitamab vedotinlocally advanced or metastatic urothelial carcinomamixed patient populationreal-world study

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 Receptordisitamab vedotinAntibodies, MonoclonalOligopeptides

Autor:innen und Institutionen

  • Department of Urology, Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Department of Urology, Jiangxi Provincial People's Hospital, Nanchang, China.
  • Department of Urology, First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Department of Urology, First People's Hospital of Jiujiang City, Jiujiang, China.
  • Jiangxi Cancer Hospital and Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zou, X. C., Xu, L. Y., Yuan, Y. Y., Zhang, G. Y., Huang, J. B., & Zeng, T. (2026). Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1815591

Vancouver

Zou XC, Xu LY, Yuan YY, Zhang GY, Huang JB, Zeng T. Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1815591

BibTeX
@article{Zou2026,
  author = {Zou, Xin Chang and Xu, Lie Yu and Yuan, Yu Yang and Zhang, Gu Yue and Huang, Jian Biao and Zeng, Tao},
  title = {Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1815591}
}
Kostenlos starten →